. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: J Biomed Inform. 2009 Jun 16;42(6):990–1003. doi: 10.1016/j.jbi.2009.05.010

Table 19.

27,648 strategies led the DIKB to predict one or more of the interactions or non-interactions shown in this table that were refuted by the validation set. For refuted interactions, asterisks indicate the drug that the DIKB considers the object of a metabolic inhibition interaction via the enzyme shown in parentheses. For refuted non-interactions, they indicate the drug that should not be affected by inhibition of the enzyme shown in parentheses.

Refuted interactions
itraconazole - fluvastatin* (CYP3A4)
fluconazole - rosuvastatin* (CYP2C9)

Refuted non-interactions
itraconazole - rosuvastatin* (CYP3A4)
clarithromycin* - fluconazole (CYP2C9)